Archive for the ‘Clinical Trials / Drug Trials’ Category
Thursday, July 17th, 2008
CHICAGO, July 17, 2008 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that the United Kingdom's Defence Science and Technology Laboratory ("Dstl") will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury. ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
- Second instance where survival increase is observed in advanced non-small cell lung cancer patients receiving Tavocept in conjunction with standard chemotherapySAN ANTONIO, July 17, 2008 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced that patients with adenocarcinoma (the most frequently occurring form of lung cancer) participating in a Phase ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
TORONTO, July 17, 2008 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. , a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today released progression free survival (PFS) data from two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
Supplemental Statistical Analysis Supports Superior Efficacy of ADVEXIN in p53 Biomarker Patient PopulationAUSTIN, Texas--(BUSINESS WIRE)--July 17, 2008--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
SAN DIEGO, July 17, 2008 /PRNewswire-FirstCall/ -- Vical Incorporated today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
PORTLAND, Ore.--(BUSINESS WIRE)--Jul 17, 2008 - Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy systems, today announced that the Biojector(R) 2000 (B2000) was used in Vical Inc.'s (Vical) first Phase 1 human trial of H5N1 pandemic influenza DNA vaccines formulated with Vical's Vaxfectin(R) adjuvant. Data ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
DANBURY, Conn., July 16, 2008 /PRNewswire-FirstCall/ -- Biodel Inc. today announced that its two pivotal Phase III VIAject(TM) clinical trials are now complete, with the last study patient visit on July 14, 2008. Results of the full trial will be released either at Biodel's poster presentation at the European Association ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
PRINCETON, N.J.--(BUSINESS WIRE)--Jul 16, 2008 - GE Healthcare's iodixanol, an isosmolar contrast medium, shows lower incidence of elevated serum creatinine (SCr) or decreased glomerular filtration rate (GFR) than iopromide, concluded a study written by a team of physicians and researchers at the Medical University of South Carolina, and published in ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
THE WOODLANDS, Texas--(BUSINESS WIRE)--July 16, 2008 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
GAITHERSBURG, Md., July 16 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Madhusudan V. Peshwa, Ph.D., Vice President Research and Development at MaxCyte, will present on Thursday, July 17, 2008 at 4:40PM EDT at IBC's Next Generation Vaccines Conference ...
Posted in Clinical Trials / Drug Trials | No Comments »
Thursday, July 17th, 2008
SEATTLE--(BUSINESS WIRE)--Jul 16, 2008 - Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced today the company will host a free webinar titled "Graphical Evaluation for Cardiovascular Safety Data in Clinical Trials" on July 17, 2008 from 8:30 to 9:30 a.m., Pacific Daylight Time. Dr. Ihab ...
Posted in Clinical Trials / Drug Trials | No Comments »
Wednesday, July 16th, 2008
BEDMINSTER, N.J.--(BUSINESS WIRE)--Jul 16, 2008 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today said that its prospective, observational study of heart failure patients showed that early evaluation of dyspnea (shortness of breath) is crucial in assessing patients with acute ...
Posted in Clinical Trials / Drug Trials | No Comments »
Wednesday, July 16th, 2008
ATLANTA--(BUSINESS WIRE)--Jul 16, 2008 - MIV Therapeutics, Inc. (OTCBB:MIVI) (Frankfurt:MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, today announced that its Protea(TM) ultra-thin cobalt-alloy bare metal stent has excelled in animal studies. The Protea is the Company's next generation ...
Posted in Clinical Trials / Drug Trials | No Comments »
Wednesday, July 16th, 2008
SAN DIEGO--(BUSINESS WIRE)--July 16, 2008 - Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced positive results from its first double-blind Phase 3 trial assessing the safety and efficacy of Prulifloxacin as a once-daily (600 mg), three-day oral therapy for infectious diarrhea. The top-line analysis of data from this study shows that Prulifloxacin ...
Posted in Clinical Trials / Drug Trials | No Comments »
Wednesday, July 16th, 2008
SAN DIEGO--(BUSINESS WIRE)--July 16, 2008 - Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company's proprietary electroporation delivery technology and, specifically, a new ...
Posted in Clinical Trials / Drug Trials | No Comments »